Office Of New Drugs Oversight Of Advisory Committees Creates Bias – Graham

The Office of New Drugs' authority over FDA advisory committees creates a bias in industry's favor, Office of Drug Safety Associate Director for Science David Graham said March 21 during a National Press Club "Newsmakers" conference in Washington, D.C